Abbvie (ABBV -1.03%), the Abbott spinoff that made its New York Stock Exchange debut at the start of the year, recently announced that its chief scientific officer will retire in the coming months. A new CSO has not yet been revealed, but is this something that investors need to watch? Can this appointment offer clues as to AbbVie's future strategy, much as a recent shake-up at Merck (MRK 0.10%) did? Health-care analyst Max Macaluso discusses this story in the following video.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.